SpectraCure AB (publ) (SPEC.ST)
SEK 3.59
(15.81%)
SEK 3.59
(15.81%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 1.00 SEK | 6871947673500.0% |
| 2022 | - SEK | 100.0% |
| 2021 | -1.00 SEK | -3435973836850.0% |
| 2020 | - SEK | 300.0% |
| 2019 | - SEK | 100.0% |
| 2018 | -13 Thousand SEK | -195.45% |
| 2017 | -4400.00 SEK | 99.98% |
| 2016 | -19.2 Million SEK | -3963.26% |
| 2015 | -472.7 Thousand SEK | -47271000.0% |
| 2014 | 1.00 SEK | 0.0% |
| 2013 | - SEK | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | - SEK | -100.0% |
| 2024 Q2 | - SEK | 0.0% |
| 2023 Q1 | - SEK | -100.0% |
| 2023 FY | 1.00 SEK | 6871947673500.0% |
| 2023 Q4 | 1.00 SEK | -100.0% |
| 2023 Q3 | 877 Thousand SEK | -7.29% |
| 2023 Q2 | 946 Thousand SEK | 0.0% |
| 2022 Q1 | -822 Thousand SEK | -325.91% |
| 2022 FY | - SEK | 100.0% |
| 2022 Q4 | - SEK | 100.0% |
| 2022 Q3 | -1.16 Million SEK | 30.62% |
| 2022 Q2 | -1.68 Million SEK | -104.99% |
| 2021 FY | -1.00 SEK | -3435973836850.0% |
| 2021 Q1 | -1.14 Million SEK | -114000100.0% |
| 2021 Q2 | -1.89 Million SEK | -65.88% |
| 2021 Q3 | -961 Thousand SEK | 49.18% |
| 2021 Q4 | -193 Thousand SEK | 79.92% |
| 2020 Q1 | - SEK | -100.0% |
| 2020 Q2 | - SEK | 0.0% |
| 2020 Q3 | - SEK | 0.0% |
| 2020 Q4 | 1.00 SEK | 0.0% |
| 2020 FY | - SEK | 300.0% |
| 2019 Q2 | - SEK | 0.0% |
| 2019 Q1 | - SEK | -100.0% |
| 2019 FY | - SEK | 100.0% |
| 2019 Q4 | 1.00 SEK | 0.0% |
| 2019 Q3 | - SEK | 0.0% |
| 2018 Q2 | - SEK | 0.0% |
| 2018 FY | -13 Thousand SEK | -195.45% |
| 2018 Q4 | 1.00 SEK | 0.0% |
| 2018 Q3 | - SEK | 0.0% |
| 2018 Q1 | - SEK | -100.0% |
| 2017 Q3 | 517.48 Thousand SEK | 51748000.0% |
| 2017 Q1 | - SEK | 100.0% |
| 2017 Q2 | 1.00 SEK | 0.0% |
| 2017 Q4 | 1.00 SEK | -100.0% |
| 2017 FY | -4400.00 SEK | 99.98% |
| 2016 Q1 | 1.00 SEK | 0.0% |
| 2016 FY | -19.2 Million SEK | -3963.26% |
| 2016 Q3 | - SEK | 0.0% |
| 2016 Q4 | -6250.00 SEK | 0.0% |
| 2016 Q2 | - SEK | -100.0% |
| 2015 Q3 | - SEK | 0.0% |
| 2015 Q4 | - SEK | 0.0% |
| 2015 Q1 | - SEK | -100.0% |
| 2015 Q2 | - SEK | 0.0% |
| 2015 FY | -472.7 Thousand SEK | -47271000.0% |
| 2014 FY | 1.00 SEK | 0.0% |
| 2014 Q4 | 1.00 SEK | 0.0% |
| 2014 Q1 | - SEK | 0.0% |
| 2013 FY | - SEK | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Acarix AB (publ) | 6.83 Million SEK | 100.0% |
| ADDvise Group AB (publ) | 121.2 Million SEK | 100.0% |
| ADDvise Group AB (publ) | 121.2 Million SEK | 100.0% |
| Arcoma AB | 28.02 Million SEK | 100.0% |
| Bactiguard Holding AB (publ) | 29.64 Million SEK | 100.0% |
| BICO Group AB (publ) | 493.1 Million SEK | 100.0% |
| Boule Diagnostics AB (publ) | 62.4 Million SEK | 100.0% |
| CellaVision AB (publ) | 126.03 Million SEK | 100.0% |
| Clinical Laserthermia Systems AB (publ) | 6.11 Million SEK | 100.0% |
| Chordate Medical Holding AB (publ) | 1.77 Million SEK | 100.0% |
| C-Rad AB (publ) | 64.09 Million SEK | 100.0% |
| Duearity AB (publ) | 4.15 Million SEK | 100.0% |
| Dignitana AB (publ) | 7.41 Million SEK | 100.0% |
| Episurf Medical AB (publ) | 3.7 Million SEK | 100.0% |
| Getinge AB (publ) | 6.41 Billion SEK | 100.0% |
| Scandinavian Real Heart AB (Publ) | -1.68 Million SEK | 100.0% |
| Iconovo AB (publ) | -4.86 Million SEK | 100.0% |
| Integrum AB (publ) | 22.36 Million SEK | 100.0% |
| Luxbright AB (publ) | 8000.00 SEK | 99.988% |
| Mentice AB (publ) | 14.1 Million SEK | 100.0% |
| OssDsign AB (publ) | 4.3 Million SEK | 100.0% |
| Paxman AB (publ) | 19.99 Million SEK | 100.0% |
| Promimic AB (publ) | 330 Thousand SEK | 100.0% |
| Qlife Holding AB (publ) | 7.29 Million SEK | 100.0% |
| SciBase Holding AB (publ) | 11.91 Million SEK | 100.0% |
| ScandiDos AB (publ) | 22.69 Million SEK | 100.0% |
| Sectra AB (publ) | 36.59 Million SEK | 100.0% |
| Sedana Medical AB (publ) | 42.97 Million SEK | 100.0% |
| Senzime AB (publ) | 20.34 Million SEK | 100.0% |
| Stille AB | 66.55 Million SEK | 100.0% |
| Vitrolife AB (publ) | 413 Million SEK | 100.0% |
| Xvivo Perfusion AB (publ) | 141.6 Million SEK | 100.0% |